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Heterogeneity of mitochondrial diseases in terms of genetic etiology and clinical 
management makes their diagnosis challenging. Mitochondrial genome, basic 
mitochondrial genetics, common mutations, and their correlation with human 
diseases is well-established now and advances in sequencing is accelerating the 
molecular diagnostics of mitochondrial diseases. Major research focus now is on 
development of mtDNA intervention techniques like mtDNA gene editing, transfer 
of exogenous genes (sometimes even entire mtDNA) that would compensate for 
mtDNA mutations responsible for mitochondrial dysfunction. Although these 
genetic manipulation techniques have good potential for treatment of mtDNA 
diseases, research on such mitochondrial manipulation fosters ethical issues. The 
present chapter starts with an introduction to the factors that influence the clinical 
features of mitochondrial diseases. Advancement in treatments for mitochondrial 
diseases are then discussed followed by a note on methods for preventing transmis-
sion of these diseases.
Keywords: mitochondrial diseases, mtDNA intervention techniques, mitochondrial 
donation, genomics advancements, reproductive techniques
1. Introduction
Mitochondria are synonymized with energy thanks to their ability to produce 
most of the Adenosine Triphosphate (ATP) through the process of Oxidative 
Phosphorylation. In addition to ATP production, several metabolic processes 
like tricarboxylic acid cycle (TCA), fatty acid oxidation, ketogenesis, urea cycle 
(partly), heme and phospholipid synthesis take place in mitochondria [1, 2]. Role of 
mitochondria in cell death (apoptosis) is also well-established [3]. Recent research 
suggests new role of mitochondria in calcium homeostasis, iron and copper 
metabolism and inflammation and immunity [4]. Though oxidative phosphoryla-
tion puts aerobes at higher level in terms of efficiency of energy production, one 
unpleasant consequence of this important process is production of reactive oxygen 
species (ROS) also known as mitochondrial ROS (mtROS). The culprit for forma-
tion of these reactive species is proton leak at the inner mitochondrial membrane. 
Formation of such species pose great threat to mitochondrial DNA (mtDNA) and 
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may lead to mitochondrial dysfunction [5]. Once thought to be uncommon, mtDNA 
diseases are now known to be quite prevalent and their definition is no more 
restricted to defects in oxidative phosphorylation alone but also include defects in 
molecular processes like mitochondrial fission, fusion and translation [6–8].
The list of common mitochondrial diseases and syndromes is quite lengthy that 
include mitochondrial encephalopathy, lactic acidosis and stroke-like episodes 
(MELAS syndrome), Leber’s hereditary optic neuropathy (LHON), myoclinic 
epilepsy with ragged-red fibers (MERRF), Leigh syndrome and Pearson syndrome, 
Kearne-Sayre syndrome (KSS), chronic progressive external ophthalmolople-
gia (CPEO) and neuropathy, ataxia and retinitis pigmentosa (NARP) [9–17]. 
Mutations in the mitochondrially-encoded genes are the most common cause 
of these diseases. Several mutations have been reported such as m.3243A > G, 
m.3271 T > C, m.1642G > A, m.9957 T > C, m.3272 T > C, m.1642G > A, 
m.1277A > G, m.13045A > C, m.13513G > A and m.13514A > G (all reported 
in MELAS [18–26]), m.8344A > G, m.8356G > A, m.3291 T > C, m.4279A > G 
(reported in MERRF [27–29]), G3460A, T14484C in LHON [30]. Recent review 
describes a comprehensive approach to study mitochondrial disorders caused by 
mutations through an example of m.3243 A > G [31].
Reviews on basic mitochondrial genetics, mutations and their correlation with 
human diseases are available [32–34]. Starting with unique features of mitochon-
dria that decide the clinical presentation of mitochondrial diseases, this review 
focusses on advancement in mitochondrial DNA manipulation. Methods for 
preventing transmission of these diseases are discussed at the end.
2. Factors that govern clinical features of mitochondrial diseases
2.1 Heteroplasmy
Presence of several thousand copies of mitochondrial genome (mtGenome) 
per cell creates two conditions; homoplasmy and heteroplasmy. When all copies of 
mtGenome are identical, the scenario is described as homoplasmy. Heteroplasmy 
is a situation in which more than one mtDNA variants exist between the cells of 
an individual or within a same cell. Often this is due to de novo mutations either 
in germ line or in somatic cells. As a result, mitochondrial dysfunction can be seen 
only in specific cells, tissues, or organs. The rate at which the regions in the mtGen-
ome evolves is much higher than that of nuclear genes. This reduces the possibility 
of all mtDNA molecules to be identical in an individual’s cells. Considering the large 
copy number of mtGenome present, detection of mtDNA mutation is difficult until 
it is spread among enough mtDNA molecules in a given cell. Only when mutated 
mtDNA exceeds threshold levels, clinical consequences of such mutations are seen 
[35]. Absence of fixed functional threshold level makes the analysis of mtDNA 
results even more complicated. Variations in threshold frequencies have been 
reported for different types of tissues and mtDNA mutations.
2.2 Mitochondrial DNA bottleneck
Mitochondrial genome, unlike its nuclear counterpart, shows uniparental transmis-
sion. Considering a single-parent origin, theoretically, mitochondrial DNA of a mother 
and her progeny should not show any variations. But, in reality, extensive variations 
have been reported in humans [36, 37]. Accumulation and enrichment of mutant mito-
chondria thus suggests presence of mitochondrial bottleneck; a concept that describes 
why mtDNA of an embryo may differ significantly from that of its mother [38].
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3. Manipulation of mitochondrial DNA
Diagnosis and monitoring clinical progression of mtDNA diseases is difficult 
due to multi-copy nature of mtGenome. Fortunately, many harmful mtDNA muta-
tions are heteroplasmic and this paves the way for curing these disorders. If mutated 
copies of mtDNAmolecules can be removed selectively from the pool of wild type 
molecules, heteroplasmy can be reduced and cellular biochemical defects can be 
cured. However, manipulating heteroplasmy has been challenging due to several 
barriers. Some of these barriers and attempts to overcome them are discussed in this 
section.
3.1 First barrier: difficulty in mitochondrial transfection
Mitochondria have two lipid bilayers that includes outer and inner membranes. 
While outer membrane allows easy transport of small molecules like ATP, proteins 
less than 10 KDaand ions, the inner mebrane brings selectivity barrier. Hydrophilic 
molecules cannot cross this barrier due to presence of cardiolipin; a hallmark mito-
chondrial lipid with four alkyl tails. It is this impermeability of inner membrane to 
the hydrophilic molecules that makes the passage of DNA through mitochondrial 
membranes difficult.
3.2 Strategies to overcome mitochondrial membrane barrier
One of the effective ways to treat mitochondrial diseases is to introduce wild 
type genes into the mitochondria. The approaches for introducing genes can be 
broadly classified into three categories namely physical, chemical, and biological 
methods. Physical methods are relatively simple and straightforward. Methods like 
microinjection, particle bombardment, electroporation and sonication have been 
used for delivering exogenous genes into the mitochondria [39, 40]. Separate carrier 
molecules are not required in these methods which eliminates the toxicity problems 
of such molecules. However, drawbacks of these methods include random distribu-
tion of DNA in mitochondrial matrix and the risk of damage of target cell during 
cell membrane penetration [40].
Many chemical-based methods have been reported for mitochondrial gene 
delivery. Considering hydrophobicity and presence of negative charges on mito-
chondrial membrane, cationic and amphiphilic carrier molecules have been used 
to enclose the negatively charged DNA [41]. Plasmid DNA was introduced to 
mitochondria using rhodamine-pDNA-nanoparticle complex [42] where the dye 
facilitated movement of nanoparticles across the plasma membrane and mito-
chondrial membrane. Mitochondria-specific liposomes were used for successful 
release of plasmid DNA in mitochondrial matrix [43], however, certain limitations 
like cytotoxicity and low transfection efficiency were noted. Improved version of 
liposome-based nanocarrier came in the form of MITO-Porter [44, 45]. Current 
research focuses on improving the mitochondrial targeting and reducing the toxic-
ity to target cells. New ligands are being explored and linked to chemically synthe-
sized carrier molecules that target the mitochondrial receptors.
Understanding of mitochondrial targeting signal peptide (MTS)-mediated 
translocation has provided a new biological approach for specific mitochondrial 
gene delivery. Carrier molecules having DNA-binding ability were conjugated to 
MTS. DNA oligomer peptide nucleic acid (PNA) that has polyamide bond rather 
than usual sugar-phosphate backbone, was conjugated to MTS and this MTS-
mediated PNA could successfully enter the mitochondrial matrix through the 
translocase of outer membrane (TOM) and that of inner membrane (TIM) [46, 47]. 
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Though this approach has some shortcomings like low mitochondrial targeting 
(as PNA tends to be localized in nucleus) and the restricted size of genes-to 
be-transferred, this is a clear indication that MTS can be successfully applied 
in mitogene delivery in near future. Use of viral vectors, especially adeno-
associated virus (AAV), have been tested for mitochondrial gene delivery [48]. 
The wild type human mitochondrial genes were added to MTS-AAV complex to 
compensate mutated and defective NADH ubiquinone oxidoreductase subunit 
4 (ND4) gene which is the culprit for LHON [49]. In addition to these physical, 
chemical, and biological methods, there are several combinatorial approaches 
that have been tested. A recent review [50] gives details of these methods and 
also discusses the need for new approaches.
3.3 Barrier 2: eliminating mutant mtDNA molecules
Elimination of mutant mtDNA molecules can reduce the threshold of mutant 
molecule load. Total elimination of mutant mtDNA is not required because a small 
reduction in mutant mtDNA load just below the threshold can improve the clinical 
scenario of a diseased person.
3.4 Strategies to selectively target mutant molecules
Construction and characterization of mitoApaLI; one of the several mitochon-
dria-targeted restriction endonucleases developed so far, and its significant role in 
shifting heteroplasmy towards one of the two mtDNA haplotypes is explained in 
detail in a recent book chapter [51]. The prerequisite (also a limiting factor) of using 
mitoREs is that the target mutation should result in a unique restriction site to avoid 
breaking of wild type mtDNA. Different methods of mitochondrial transfection 
and strategies to deal with heteroplasmy are summerized in Figure 1.
Two recent gene editing systems namely mitochondria-targeted transcription 
activator-like effector nucleases (mitoTALENs) and mitochondria-targeted zinc 
finger nucleases (mtZFN) can selectively target single nucleotide mutations and can 
degrade them. Minczuk and Gammage laboratories have extensively used mtZFN 
to shift heteroplasmy [52, 53]. The mitoTALENs have been used to target specific 
mutations from animal and human-derived cells [54]. Although these gene therapy 
approaches are quite promising, we need to be careful because of the risk involved 
in this approach. mtDNA copy number may go down significantly and there may 
be undesirable off-target effects while attempting elimination of mutated copies. 
Crisper-Cas 9 cannot be used for this purpose because it needs single-guide RNA for 
gene editing and RNA import in mitochondria is restricted [55].
4. Decrease in NAD+ levels
Nicotinamide adenine dinucleotide oxidized (NAD+) is a coenzyme required 
for action of many enzymes like polyADP ribose polymerase (PARP) and sirtuin 
deacetylases. Substantial decrease in NAD+concentration and the ratio of NAD+/
NADH was reported in the cells having defective mitochondria [56]. Defective 
respiratory chain cannot reoxidize NADH to oxygen. This results in reduction 
of pyruvate to lactate by lactate dehydrogenase generating NAD+. Transport of 
excess lactate outside the cell leads to lactate acidemia, which is a common feature 
of mitochondrial diseases. Increasing the cellular levels of NAD+ either through 
supplementation or through bringing changes in enzymes involved in its synthe-
sis have been reported [57]. A recent approach tested in mice was to reoxidize 
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extracellular lactate to pyruvate and bring it back to the cell for its re-reduction by 
lactate dehydrogenase thus increasing NAD+/NADH ratio [58].
5. Prevention of transmission of mitochondrial diseases
5.1 Options to prevent transmission
Mitochondrial DNA is maternally inherited and genetic bottleneck makes it even 
more peculiar. Therefore, options different from those with nuclear genetic defects 
must be considered. It is important to know which mutation a woman carries 
and its level; especially in those cases who harbor heteroplasmic mtDNA muta-
tions. Genetic diagnosis and expert counseling is invaluable for such cases. Post-
counseling options include voluntary childlessness and adoption. Prenatal testing 
and preimplantation genetic diagnosis (PGD) are recently available alternatives. 
PGD includes in vitro fertilization (IVF) and embryo development to blastocyst 
stage. Because of inherent issues with IVF, PGD has limited chance to succeed.
Figure 1. 
The figure is a schematic representation of different methods of mitochondrial transfection and strategies 
to deal with heteroplasmy. Abbreviations used in the figure are: Outer mitochondrial membrane (OMM), 
intermembrane space (IMS), inner mitochondrial membrane (IMM), mitochondrial target signal peptide 
(MTS), translocase of outer membrane (TOM), translocase of inner membrane (TIM), adeno-associated 
virus (AAV) and mitochondrial DNA (mtDNA).
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5.2 Mitochondrial replacement therapy (MRT) or mitochondrial donation
MRT is probably the only way available to those couples who are suffering from 
mitochondrial disease and wish to have a healthy child. In such cases, nucleus is 
taken from a mother carrying defective mitochondria and transferred to an enucle-
ated oocyte or egg of a woman with healthy mitochondria. Embryo formed after 
this procedure (also called as three parent embryo) will have nuclear DNA from 
both parents but mitochondrial DNA from another mother. Ideally such embryo 
should be free from defective mitochondria. Using this technique in human 
oocytes, good quality embryos could be formed as reported by several workers [59, 
60]. Though potentially this is a great advancement, mitochondrial donation may 
raise ethical issues [61]. Also some workers observed that the nucleus which was 
transferred to enucleated oocyte/egg showed presence of contaminating defec-
tive mitochondria. Enrichment of such contaminating mitochondria may cause 
mitochondrial disease in individuals generated through MRT. This issue becomes 
more sensitive when female embryos are generated after MRT because they will be 
passing on their defective mitochondria to the next generation. MRT females may 
show same mitochondrial disease and infertility as their mothers. In future, better 
understanding of maternal inheritance of mitochondria will improve the efficacy 
of this therapeutic method and make it a sustainable approach for betterment of 
individuals across the generations. Another issue that may hamper the progress 
of mitochondrial donation is availability of oocyte donors because this involves 
hormonal treatment.
6. Conclusions
Advances in DNA sequencing are accelerating the diagnosis of mitochondrial 
diseases and helping in assessment of heteroplasmy levels. Although molecular 
diagnosis is crucial, it can only identify the problem but cannot solve it. Input 
from reproductive biologists are equally important for comprehensive analysis and 
personal care of diseased individuals. Development of new treatments through 
further advancements in gene therapy holds great promise for the sufferers of 
mitochondrial disease.
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